The Testing Evidence for Using Mebendazole for Treating Adrenal Gland Cancer

ByPrimary Researcher

Executive Summary

  • This article covers the evidence I could find for Mebendazole as a treatment for Adrenal Gland Cancer.

Article Summary

Studies demonstrate that Mebendazole is effective against cancer, we then cover how Mebendazole works against cancer by explaining the mechanisms of action, and then the impacts of Mebendazole on cancer.

Introduction

This article provides an overview covering the evidence for Mebendazole and related drugs versus Adrenal Gland Cancer.

Many articles on this website cover the evidence for the benefits of Mebendazole for cancer. But the question of which specific cancers Mebendazole has been proven effective is a constant source of questions.

The most common Benzimidazoles are Fenbendazole, Mebendazole and Albendazole. In our analysis, we include research for all three drugs together in articles as they are very similar to one another and it improves the ability to tie together different studies. You may see the following terms/acronyms used.

  • FZ or FBZ means Fenbendazole
  • MBZ means Mebendazole
  • AZ means Albendazole

Go to top

Cancer Type #13: Adrenal Gland Cancer

The following quote is from the article Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells.

Benzimidazoles, specifically mebendazole and albendazole, have shown in vivo antitumor activity against a range of cancers, including hepatocellular, lung, and adrenocortical carcinoma (5, 6, 21).

The following quote is from the article Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects.

Treatment with repurposing pleiotropic benzimidazole antihelminthics, like mebendazole, albendazole, and flubendazole has recently opened a new window, owing to their easy access, low cost as a generic drug, and long track record of safe use in the human population. This review highlights the outcomes of preclinical and clinical studies of these drugs as a potent anticancer agent(s) conducted in the last two decades. Substantial preclinical studies, as well as limited clinical trials, suggest noteworthy anticancer potency of these pleiotropic benzimidazoles, particularly as potent microtubule disrupting, anti-angiogenic, and anti-metastatic agents, inhibitors of the immune checkpoint, hypoxia-inducible factor, epithelial-mesenchymal transition, cancer stemness, and multidrug resistance protein 1, and inducers of apoptosis and M1 polarization. These anticancer effects are attributed to multiple action points, including intrinsic apoptosis, canonical Wnt / β-catenin, JAK / STAT-3, JNK, MEK / ERK, and hedgehog signaling pathways. The effective anticancer properties of mebendazole, albendazole, and flubendazole either alone or synergistically with frontline drugs, warrant their validation through controlled clinical trials to use them as promising avenues to anticancer therapy.

The anticancer effect of MBZ is observed in a 48 − years-old human subject carrying conventional therapy-resistant metastatic adrenocortical carcinoma. Monotherapy with 100 mg of MBZ (twice daily) makes the patient stable following an initial dropping of metastasis and this stability is maintained during the entire treatment period of 19 months. However, a progression of the disease was observed following 24 months of MBZ therapy [102]. The result of a case study also establishes the promising

Go to top

Adding up the Studies of Mebendazole Versus Cancer

There are many studies of Fenbendazole, Mebendazole, Albendazole, and other Benzimidazole derivatives versus cancer.

Due to the success of these studies and the information published in the study publications, the specific mechanisms by which these Benzimidazole-based Anthelmintics work against cancer are at this point well understood. There has not been a study published for every cancer type using one of the Benzimidazole derivatives. There are a very large number of different cancer types and limited funding for this type of research.

Go to top

How Many Major Cancer Types Are There Studies For?

When I completed my analysis, I found 18 different types of cancer types which demonstrated effectiveness versus cancer. In many cases, these different cancer types had multiple cancer studies testing the different Benzimidazole derivatives.

Cancer centers do not apply the large body of published studies on the effectiveness of Benzimidazole derivatives to include as part of their treatment offerings. This is true even though Fenbendazole has been demonstrated to improve chemotherapy outcomes.

To understand the mechanisms by which Benzimidazole derivatives work against cancer, see the following few examples. To see all of the known mechanisms that I have compiled from all of the studies see the article on the mechanisms listed below.

Go to top

The Multiple Mechanisms by Which Mebendazole Works Against Cancer

There are many ways in which Mebendazole works against cancer including.

  • Reducing metastasis
  • Increase autophagy
  • Increase cancer cell death or apoptosis
  • and much more

This topic is covered in the article By How Many Different Mechanisms Does Menbendazole Fight Cancer?